Loading clinical trials...
Loading clinical trials...
The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area. Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy will be assessed by evaluating implant success rate.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Banner - University Medical Center Phoenix
Phoenix, Arizona, United States
Cardiology Associates Medical Group
Ventura, California, United States
Washington Hospital Center
Washington D.C., District of Columbia, United States
Sarasota Memorial Health Care System
Sarasota, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Cardiology Associates
Tupelo, Mississippi, United States
NYU Langone Health
New York, New York, United States
Weill Cornell Medicine
New York, New York, United States
Start Date
December 12, 2022
Primary Completion Date
January 9, 2024
Completion Date
October 8, 2024
Last Updated
March 18, 2025
194
ACTUAL participants
Solia S lead
DEVICE
Lead Sponsor
Biotronik, Inc.
NCT07221682
NCT03008291
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07290595